preparation method of disodium sulfodehydroabietate (DSDA) and composition

Abstract

The invention discloses disodium sulfodehydroabietate (DSDA) and a composition, a preparation method and application thereof in medicaments for preventing hyperacid peptic ulcer and gastrointestinal inflammation. A patent application disclosed by CN00818150.0 is of the opinion that monosodium sulfodehydroabietate is superior to disodium salt, but does not further disclose test conditions and dataconclusion; moreover, the pharmacological action and clinical application of the disodium salt deserve further research. The invention compares the in-vitro acid making effects of monosodium salt andthe disodium salt, the dissolution of the monosodium salt and the disodium salt in artificial gastric juice and intestinal juice as well as the clinical efficacies in treating gastric ulcer, acute gastritis and acute attack of chronic gastritis. Results show that DSDA has the advantages that DSDA has stronger acid-making capability during treating the gastric ulcer, acute gastritis and acute attack of chronic gastritis and faster dissolution speed in stomach and intestine; and medicaments prepared from the DSDA have better curative effect and quick response.

Description

technical field [0001] The present invention relates to sulfonated dehydroabietic acid disodium, in particular to sulfonated dehydroabietic acid disodium, its composition, preparation method and its use in medicines for preventing and treating hyperacidity peptic ulcer and gastrointestinal inflammatory disease application. Background technique [0002] The compound sulfonated dehydroabietic acid was reported as early as the 1930s as an intermediate for the preparation of pure dehydroabietic acid; it was reported in the 1970s that its derivatives can be used as detergents, but as drugs, especially for gastric Drug research for the prevention or treatment of intestinal diseases is very rare. [0003] Gastrointestinal diseases are one of the common and frequently-occurring diseases, among which ulcer disease is the most common, and the total incidence rate accounts for about 10-20% of the world's population. Gastrointestinal diseases include: peptic ulcer, gastritis, intestin...

AI Technical Summary

Problems solved by technology

[0009] It can be seen that the scope of protection of the above application is very wide. When treating inflammatory bowel diseases, all salts with sulfonated dehydroabietic acid belong to the scope of protection, but in such a broad scope of protection, it can be supported by instructions It is only the monosodium salt of sulfodehydroabietic acid, and other salts of sulfodehydroabietic acid are not supported by the instructions. Their pharmacological effects and clinical application are worthy of further study

Images